1. Impact of Atezolizumab + Bevacizumab Therapy on Health-Related Quality of Life in Patients with Advanced Hepatocellular Carcinoma.
- Author
-
Shomura, Masako, Okabe, Haruka, Sakakibara, Maya, Sato, Emi, Shiraishi, Koichi, Arase, Yoshitaka, Tsuruya, Kota, Mishima, Yusuke, Hirose, Shunji, and Kagawa, Tatehiro
- Subjects
THERAPEUTIC use of antineoplastic agents ,THERAPEUTIC use of monoclonal antibodies ,HEALTH status indicators ,DRUG side effects ,STATISTICAL significance ,RESEARCH funding ,BEVACIZUMAB ,TREATMENT effectiveness ,TREATMENT duration ,CANCER patients ,BLOOD protein disorders ,NURSING interventions ,DESCRIPTIVE statistics ,LONGITUDINAL method ,KAPLAN-Meier estimator ,LOG-rank test ,QUALITY of life ,DRUG efficacy ,DATA analysis software ,CONFIDENCE intervals ,HEPATOCELLULAR carcinoma ,OVERALL survival - Abstract
Simple Summary: This study explored the factors associated with treatment efficacy, treatment duration, and overall survival (OS) in 58 patients with advanced hepatocellular carcinoma undergoing atezolizumab + bevacizumab therapy. Better baseline cognitive and physical function scores and absence of severe (grade ≥ 2) hypoalbuminemia were associated with an improved objective response rate, longer treatment duration, and better OS. These findings highlight the importance of monitoring and managing treatment-related adverse events and maintaining health-related quality of life through multidisciplinary care. Background/Objectives: Health-related quality of life (HRQoL) is critical in patients with hepatocellular carcinoma (HCC). It has become a key endpoint in the evaluation of new therapies, including atezolizumab + bevacizumab (Atezo + Bev) therapy. Methods: This study explored the factors associated with treatment efficacy, treatment duration, and overall survival (OS) in patients with advanced HCC undergoing Atezo + Bev therapy. We included 58 consecutive patients with HCC receiving Atezo + Bev from 19 November 2020, to 28 December 2023, who were followed up until the end of the study or death. We analyzed the relationships between baseline characteristics, adverse events (AEs), and HRQoL and efficacy, OS, and treatment duration. Results: The demographic (older men) and baseline characteristics (Child–Pugh score of 5, Barcelona Clinic Liver Cancer Stage C) were consistent with those of previous studies. The treatment demonstrated promising efficacy with a disease control rate of 71.2%, but HRQoL scores in five functional domains and seven symptoms worsened significantly within the first 3 months. Notably, better baseline cognitive and physical function scores and absence of severe (grade ≥ 2) hypoalbuminemia were associated with an improved objective response rate, longer treatment duration, and better OS. Conclusions: These findings underscore the importance of monitoring and managing treatment-related AEs and maintaining the HRQoL. They also highlight the crucial and reassuring role of multidisciplinary care in enhancing treatment outcomes in this cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF